AURIEL‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis

BACKGROUND: MSB11022 is a proposed adalimumab biosimilar. OBJECTIVES: To compare the efficacy, safety and immunogenicity of MSB11022 with reference adalimumab. METHODS: AURIEL‐PsO was a double‐blind randomized controlled equivalence trial, in which patients with moderate‐to‐severe chronic plaque‐typ...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Br J Dermatol
Auteurs principaux: Hercogová, J., Papp, K.A., Chyrok, V., Ullmann, M., Vlachos, P., Edwards, C.J.
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2019
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7027805/
https://ncbi.nlm.nih.gov/pubmed/31206593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjd.18220
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires